Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547261 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00547261 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 6 participants.
The verdict
NCT00547261, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
Interventions
- DRUG SSR97225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547261
The ClinicalTrials.gov registry entry for NCT00547261 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SSR97225 is the first listed.
NCT00547261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547261 about?
NCT00547261 is a clinical study titled "Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer". The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
What is the current status of trial NCT00547261?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-10. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00547261?
The interventions under investigation include: SSR97225 (DRUG).
Who is sponsoring clinical trial NCT00547261?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.